Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study.

@article{Redman2007LackOA,
  title={Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study.},
  author={Leanne Maree Redman and Lilian de Jonge and Xiaobing Fang and Betsy Gamlin and David P Recker and Frank L Greenway and Steven R. Smith and Eric Ravussin},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2007},
  volume={92 2},
  pages={527-31}
}
OBJECTIVE Our objective was to test the safety and metabolic effects of a novel beta(3)-adrenoreceptor agonist (TAK-677) in humans. DESIGN, SETTING, AND PARTICIPANTS Sixty-five obese (body mass index = 33.9 +/- 2.1 kg/m2, mean +/- se) men and women (31.4 +/- 0.9 yr) participated in a double-blind placebo-controlled study at an institutional research… CONTINUE READING